MedTrace Logo

Modulation of Fibrosis-inducing Pathways in Acute Myocardial Infarction

NCT05122741 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-01-25

No results posted yet for this study

Summary

This is a single-center, prospective, observational controlled cohort study designed to describe the role of WNT/B-catenin signaling and adenosine system after an acute myocardial infarction, correlating it with clinical markers of fibrosis/remodeling (primary objective). The modulation of the aforementioned molecular patterns will also be evaluated in light of the type of P2Y12 inhibitor implemented (ticagrelor or prasugrel) to identify variations in response (secondary objective).

Conditions

Interventions

DRUG

P2Y12 Potent Inhibitor + Aspirin for STEMI patients

Patients will undergo primary percutaneous coronary intervention and DAPT with potent P2Y12 inhibitor (ticagrelor or prasugrel + aspirin)

DRUG

Clopidogrel + Aspirin for CCS patients

Patients will undergo elective percutaneous coronary intervention and DAPT with non-potent P2Y12 inhibitor (clopidogrel + aspirin)

Sponsors & Collaborators

  • Natasha Irrera

    collaborator UNKNOWN

  • Gianluca Di Bella

    collaborator UNKNOWN

  • Antonio Micari

    collaborator UNKNOWN

  • Roberto Licordari

    collaborator UNKNOWN

  • University of Messina

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2023-11-01
Completion
2023-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05122741 on ClinicalTrials.gov